Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.360 +0.010 (+0.74%)
Streaming Delayed Price Updated: 12:52 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,111,471
Open 1.300
Bid (Size) 1.360 (4)
Ask (Size) 1.370 (9)
Prev. Close 1.350
Today's Range 1.242 - 1.385
52wk Range 1.260 - 16.52
Shares Outstanding 35,937,937
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
-89.8%
-89.8%
1 Month
-1.4%
-1.4%
3 Month
-89.4%
-89.4%
6 Month
-87.9%
-87.9%
1 Year
-90.8%
-90.8%

More News

Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Via Benzinga
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
From Pliant Therapeutics, Inc.
Via GlobeNewswire
What's going on in today's after hours session
Via Chartmill
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future
Via Benzinga
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Get insights into the top gainers and losers of Monday's after-hours session.
Via Chartmill
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Here are the top movers in Monday's session.
Via Chartmill
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
Which stocks are gapping on Monday?
Via Chartmill
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Unusual volume stocks in Wednesday's session
Via Chartmill
Which stocks are experiencing notable movement on Monday?
Via Chartmill
Crude Oil Rises Sharply; Manhattan Associates Shares Slide
Via Benzinga
Exposures Fossil Fuels

Frequently Asked Questions

Is Pliant Therapeutics, Inc. - Common Stock publicly traded?
Yes, Pliant Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Pliant Therapeutics, Inc. - Common Stock trade on?
Pliant Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pliant Therapeutics, Inc. - Common Stock?
The ticker symbol for Pliant Therapeutics, Inc. - Common Stock is PLRX on the Nasdaq Stock Market
What is the current price of Pliant Therapeutics, Inc. - Common Stock?
The current price of Pliant Therapeutics, Inc. - Common Stock is 1.360
When was Pliant Therapeutics, Inc. - Common Stock last traded?
The last trade of Pliant Therapeutics, Inc. - Common Stock was at 04/01/25 12:52 PM ET
What is the market capitalization of Pliant Therapeutics, Inc. - Common Stock?
The market capitalization of Pliant Therapeutics, Inc. - Common Stock is 48.88M
How many shares of Pliant Therapeutics, Inc. - Common Stock are outstanding?
Pliant Therapeutics, Inc. - Common Stock has 49M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.